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Abstract  50 
Background. This open-label randomized controlled trial in infants compared safety, 51 
tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) 52 
formulated with the preservative 2-phenoxyethanol (2-PE) in a multidose vial (MDV) to the 53 
current PCV13 without 2-PE in a single-dose syringe (SDS). 54 
Methods. Gambian infants were randomized 1:1 to receive PCV13 as either MDV or SDS at 55 
ages 2, 3, and 4 months. Serotype-specific antipneumococcal antibody responses and 56 
opsonophagocytic activity ([OPA]; subset) were measured at age 5 months. Noninferiority 57 
was declared if the lower bound of the 97.5% CI for the difference (MDV-SDS) in 58 
proportions of subjects achieving IgG concentrations ≥0.35 ug/mL (primary endpoint) was 59 
greater than 10%. IgG geometric mean concentrations (GMCs) were noninferior if the lower 60 
limit of the two-sided 97.5% CI of the geometric mean ratio (MDV vs SDS) was greater than 61 
0.5. Reactogenicity and other adverse events were collected.  62 
Results. 500 participants were randomized and vaccinated; 489 (MDV: n=245; SDS: n=244) 63 
completed the trial. Noninferiority of MDV was demonstrated for all serotypes as measured 64 
by percentage of subjects achieving antibody responses above ≥0.35 ug/mL. IgG GMCs 65 
(coprimary endpoint) also demonstrated noninferiority of MDV; OPA results supported these 66 
findings. Safety and tolerability were comparable between groups. 67 
Conclusions. PCV13 in MDV was safe and immunogenic when administered according to 68 
the routine schedule to infants. MDV was noninferior to SDS for all 13 pneumococcal 69 
serotypes. Comparable immunogenicity and safety profiles of PCV13 MDV and SDS suggest 70 
PCV13 MDV can help optimize vaccination in resource-limited settings. (ClinicalTrials.gov 71 
NCT01964716 https://clinicaltrials.gov/ct2/show/NCT01964716)  72 
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Introduction 75 
The prevention of pneumococcal disease remains a major international public health priority 76 
due to high disease burden and associated mortality in children, especially in developing 77 
countries [1-3]. Pneumococcal conjugate vaccines (PCVs) are proven to prevent overall 78 
pneumococcal disease by decreasing disease burden and nasopharyngeal carriage caused by 79 
serotypes included in the vaccines [4-8]. In many parts of Africa, obstacles still exist that 80 
slow the wider uptake of PCVs, including available vaccine preparations. The 13-valent PCV 81 
(PCV13), which includes the largest number of serotypes in its formulation, is currently only 82 
available in single-dose vials (SDV) and syringes (SDS). Pneumococcal conjugate vaccines, 83 
including PCV13 SDV, have been prequalified by the World Health Organization (WHO) for 84 
use in the developing world [9]. Most vaccines used routinely in Africa are formulated in 85 
multidose vials (MDV) to maximize cold-chain storage efficiency, and serve as an important 86 
resource for vaccine introduction in resource-limited countries [10,11]. In 2010 the 87 
manufacturer of PCV13 (Pfizer Inc, New York, NY) entered into an agreement with the 88 
GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization) aiming to 89 
increase access to PCV13 in GAVI-eligible countries [12]. To meet the supply needs of this 90 
program, the manufacturer developed a formulation containing the preservative 2-91 
phenoxyethanol (2-PE), a phenolic derivative currently used as a preservative in other 92 
commercially available multidose vial presentations of pediatric vaccines [13]. This 4-dose 93 
MDV presentation would help optimize vaccine delivery and facilitate sustainable coverage.  94 
General concerns regarding vaccines in multidose vials include contamination risk and 95 
potential for wastage. PCV13 formulated with 2-PE as a preservative meets stringent 96 
pharmacopeia class B requirements for antimicrobial suppression that were previously 97 
accepted by the WHO. In addition, the multidose vial can be stored refrigerated and is 98 
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acceptable for use up to 28 days after initial dose removal. The PCV13 MDV presentation 99 
was recently prequalified by the WHO [14], licensed by the European Medicines Evaluation 100 
Agency [15], and licensed in India based on data from this clinical trial. The MDV 101 
presentation will be crucial in sustaining PCV delivery across resource-limited settings and 102 
maintaining the protection from disease that PCV13 already provides. 103 
We present here an open-label randomized vaccine trial conducted in The Gambia to 104 
compare the safety, tolerability, and immunogenicity of PCV13 with 2-PE presented in a 105 
multidose vial (PCV13 MDV) to that of PCV13 without 2-PE presented in a single-dose 106 
syringe (PCV13 SDS).  107 
Methods 108 
Trial design and population 109 
This phase 3, open-label randomized controlled trial (ClinicalTrials.gov, NCT01964716) was 110 
conducted between January and September, 2014, in The Gambia at the Medical Research 111 
Council (MRC) Unit Fajara. Participants were enrolled at the routine Expanded Programme 112 
on Immunization clinic at the Fajikunda Major Health Centre in Western Gambia. The trial 113 
was conducted per ethical principles derived from the Declaration of Helsinki and in 114 
compliance with International Conference on Harmonisation and Good Clinical Practice 115 
guidelines. The trial protocol and relevant documents were reviewed and approved by the 116 
National Regulatory Authority and the Gambian Government/MRC Joint Ethics Committee. 117 
Written informed consent was obtained from parents of each participant before enrollment 118 
and before any trial-related procedure was performed. 119 
The primary objective was to demonstrate noninferiority of immune responses induced by 120 
PCV13 MDV compared with PCV13 SDS as measured by serotype-specific immunoglobulin 121 
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G (IgG) concentrations 1 month after infant series completion. Safety profiles of each 122 
formulation were measured by rates of local reactions, systemic events, and adverse events 123 
(AEs). The secondary objective was to assess immune responses induced by PCV13 MDV 124 
relative to PCV13 SDS as measured by serotype-specific opsonophagocytic activity (OPA) in 125 
a subset of subjects. 126 
Healthy infants aged 42 to 70 days weighing 3.5 kg or more at enrollment were eligible to 127 
participate. Infants with known or suspected immune deficiency or suppression, severe acute 128 
or chronic medical conditions, neurologic disorders, known major or congenital 129 
malformations, any contraindication to vaccination with pneumococcal conjugate vaccine, 130 
previous vaccination with pneumococcal vaccine, or a history of culture-proven invasive 131 
disease caused by Streptococcus pneumoniae were excluded from the trial. 132 
Randomization 133 
In this open-label trial, participants were randomly assigned 1:1 to receive 3 doses of either 134 
PCV13 MDV or SDS. Randomization was performed using sequential allocation to trial 135 
groups based on a randomization sequence prepared by the sponsor, and provided as 136 
individual randomization envelopes.  137 
Trial vaccines and vaccination schedule 138 
PCV13 contains saccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 139 
18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria toxin cross-reactive 140 
material 197. Each 0.5-mL dose contains 2.2 μg of each saccharide, except for 4.4 μg of 6B, 141 
5 mM succinate buffer, 0.02% polysorbate 80, and 0.125 mg aluminum as aluminum 142 
phosphate. PCV13 MDVs also contain 4 mg of 2-phenoxyethanol (2-PE, the concentration of 143 
which is within the range of 2-PE concentrations used in other licensed vaccines presented in 144 
MDV formulations) per 0.5-mL dose. Four doses of PCV13 (2.0 mL) are contained within 145 
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each MDV; for this trial, only 1 dose was used from each vial to allow for 1:1 vaccine 146 
accountability (1 vial to 1 subject) in a clinical trial conducted per Good Clinical Practice 147 
guidelines. This study compared responses to PCV13 with and without 2-PE, which has 148 
already been proven an effective preservative [16]. 149 
Participants received 1 dose (0.5 mL) of PCV13 MDV or SDS at approximately 2, 3, and 4 150 
months of age per the Gambian immunization schedule, into the left anterolateral thigh. A 151 
range of 42 to 70 days of age was allowed for the 2-month visit, with subsequent visits 28 to 152 
42 days following the previous visit. Other injectable vaccines routinely administered at this 153 
age (pentavalent vaccine containing diphtheria, whole-cell pertussis, tetanus, Haemophilus 154 
influenzae type b, and hepatitis B virus antigens) were given into the contralateral limb at the 155 
same time as PCV13. Children also received oral rotavirus and polio vaccines according to 156 
local guidelines.  157 
Safety assessments 158 
An experienced physician independent of the trial was available onsite and served as a local 159 
safety monitor to provide support for any potential safety issues. The sponsor also provided a 160 
data monitoring committee (DMC) independent of the trial site to periodically review safety 161 
data. Local reactions and systemic events were monitored for at least 30 minutes after each 162 
vaccination and from days 2 to 6 after each vaccination (day 1 being the day of vaccination); 163 
events were recorded in electronic diaries (e-diaries) by trained field workers during daily 164 
home visits. Local reactions included redness, swelling, and tenderness at the PCV13 165 
injection site. Systemic events included fever (temperature ≥38.0°C), changes in appetite, 166 
sleep, and irritability; antipyretic use was also documented. If any local or systemic event 167 
persisted at day 6 and/or antipyretic use continued at day 6, field workers continued daily 168 
visits and completed the e-diary until resolution of either. Persistent fever or development of 169 
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other symptoms triggered a referral to the safety nurse and trial physician. A rapid diagnostic 170 
test for malaria parasitemia was conducted whenever a temperature reading ≥38.0°C was 171 
obtained. Any other AEs and serious AEs (SAEs) occurring between the signing of the 172 
informed consent form and the postvaccination blood draw were recorded. The relationship 173 
between AEs and the trial vaccine received was characterized as related or not related by the 174 
trial physicians. 175 
Immunogenicity assessments 176 
One venous blood sample (up to 5 mL) was collected 1 month after dose 3. Blood samples 177 
were transported to the MRC laboratory within 4 hours of collection, and serum was 178 
separated, barcoded, stored at −80°C and shipped to the sponsor for analysis. For all 179 
participants, a standardized enzyme-linked immunosorbent assay measured the concentration 180 
of serotype-specific IgG to the 13 pneumococcal vaccine serotypes [17-19]. 181 
Functional antibodies to the 13 serotypes were assessed by OPA assays [20,21] and were 182 
performed in a randomly selected subset of samples to ensure approximately 100 valid OPA 183 
results per serotype per group. To ensure 100 valid and determinate results for each serotype 184 
per treatment group, 160 subjects were randomly chosen from each treatment group. Invalid 185 
or indeterminate results were excluded from analysis, and samples with insufficient blood 186 
volume were not tested. 187 
Statistical analysis 188 
The WHO has established criteria for licensing new PCV formulations, which must 189 
demonstrate noninferiority to a current formulation for mean IgG concentrations and 190 
proportion of vaccinees achieving IgG concentrations ≥0.35 g/mL, the accepted correlate of 191 
protection against invasive pneumococcal disease, all measured 1 month after primary series 192 
completion [22-24]. 193 
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The primary endpoint for each vaccine group was the proportion of participants achieving a 194 
serotype-specific IgG concentration ≥0.35 μg/mL 1 month after dose 3. The coprimary 195 
endpoint was the serotype-specific IgG geometric mean concentration (GMC) one month 196 
after dose 3. The WHO [25] guidance calls for control of the type 1 error rate to be pre-197 
specified for multiple endpoints. As there are 2 primary comparisons (GMC or % responder), 198 
a Bonferroni correction was applied (split the 5% type 1 error rate evenly for comparison of 199 
each serotype). Therefore, 97.5% CIs were used for multiple primary comparisons. For the 200 
primary endpoint, noninferiority for a serotype (MDV relative to SDS) was achieved if the 201 
lower limit of the two-sided 97.5% CI of difference in proportions (MDV−SDS) was greater 202 
than −10%. For IgG GMCs, noninferiority for a serotype was claimed if the lower limit of the 203 
two-sided 97.5% CI of the geometric mean ratio (GMR) (MDV relative to SDS) was greater 204 
than 0.5. The overall noninferiority of immune response of the PCV13 MDV to the PCV13 205 
SDS was declared if noninferiority for either the primary or the coprimary endpoint was 206 
demonstrated for all 13 serotypes. 207 
Exact, unconditional, 2-sided, 95% CIs on the proportion were computed using the F 208 
distribution. The differences in proportions for the vaccine groups were calculated with 209 
97.5% CIs for IgG. Log transformation was used for GMRs. The OPA analysis for each 210 
vaccine group calculated the serotype-specific OPA geometric mean titers (GMTs) for each 211 
pneumococcal serotype 1 month after dose 3. The evaluable immunogenicity population was 212 
the primary analysis population, and included infants who received all assigned vaccine 213 
doses, adhered to protocol requirements, had ≥1 valid and determinate assay result, and had 214 
no major protocol violations. The safety analysis included all subjects who received ≥1 dose 215 
of PCV13. 216 
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Sample size 217 
Sample size was based on simulations for proportions of responders with IgG antibody 218 
concentrations ≥0.35 µg/mL and for ratios of the geometric mean IgG concentrations for the 219 
MDV group relative to the SDS group. The variance-covariance input matrix and the mean 220 
vector for generating the random samples from the multiple-normal distribution were based 221 
on immunogenicity data from a previous Pfizer trial [26]. One thousand studies with 200 222 
participants per group were generated for the simulations. The sample size was chosen to 223 
meet the WHO criteria [25], with Type-I error controlled by Bonferroni’s method for GMC 224 
and responder hypotheses (97.5% CIs were used for testing). Using these criteria, the trial 225 
had ≥90% power to achieve the criteria from the simulation. Estimating a dropout rate of 226 
20%, 500 participants (250 per group) were recommended for enrollment. 227 
Results 228 
Recruitment occurred between January 9 and May 19, 2014, and the last study visit was 229 
completed on September 1, 2014. Of 526 participants assessed for eligibility, 500 were 230 
enrolled, randomized, and vaccinated with either PCV13 MDV or SDS (250 per group) 231 
concomitantly with routine vaccines (Figure 1). Overall, 489 (97.8%) participants completed 232 
the blood draw 1 month after dose 3 and were included in the evaluable immunogenicity 233 
population (245 and 244 in the PCV13 MDV and SDS groups, respectively). Demographic 234 
characteristics of the evaluable immunogenicity population were similar between the vaccine 235 
groups (Table 1). Safety was assessed in all 500 participants who received ≥1 dose of trial 236 
vaccine. Characteristics of participants in the safety population were comparable to those in 237 
the evaluable immunogenicity population.  238 
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Immunogenicity 239 
Pneumococcal IgG Concentrations ≥0.35 µg/mL 240 
The numbers of participants in each trial arm achieving a pneumococcal IgG concentration 241 
≥0.35µg/mL are compared in Table 2. More than 95% of children achieved IgG 242 
concentrations 0.35 g/mL 1 month after dose 3 for each of the 13 serotypes in both vaccine 243 
groups, and the noninferiority criterion was met for this endpoint.  244 
Pneumococcal IgG Geometric Mean Concentrations 245 
One month after dose 3, GMCs were similar in both vaccine groups for the majority of 246 
serotypes. For this coprimary endpoint, noninferiority between the PCV13 MDV group and 247 
the PCV13 SDS group was demonstrated for all 13 serotypes (Table 3).  248 
Pneumococcal OPA Geometric Mean Titers 249 
The OPA GMTs for all serotypes were determined for a subset of subjects in each vaccine 250 
group (MDV, 156–160 subjects; SDS, 155–160 subjects). GMTs were similar in both groups 251 
for the majority of serotypes, except serotype 3, for which titers were statistically 252 
significantly lower in the MDV group, and serotype 18C, for which titers were statistically 253 
significantly higher in the MDV group (Table 4). All lower limits of the 95% CIs of OPA 254 
GMRs comparing MDV to SDS were greater than 0.5 except for serotype 14, which was 255 
slightly lower (ratio 0.7; 95% CI [0.48, 1.08]) (Table 4). Reverse cumulative distribution 256 
curves showing OPA titers for each PCV13 serotype 1 month after dose 3 indicate that levels 257 
were similar across the full range of OPA titers for the majority of serotypes in both vaccine 258 
groups (Supplementary Figure 1). 259 
 260 
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Safety 261 
Local reactions and systemic events after each vaccination were comparable between vaccine 262 
groups, were mainly mild, and are summarized in Table 5. Local reactions were reported 263 
mainly on day 2 (roughly 24 hours after vaccination) and generally lasted <72 hours. 264 
Proportions of participants reporting redness and swelling at the vaccination site were low in 265 
both groups after any dose. No participant experienced a severe local reaction. For all doses, 266 
fever rates were comparable in both groups and generally low (1.2%–3.6%), and no 267 
participant experienced a fever >40°C. Although documented fever was rare, antipyretic 268 
medication was used in up to 23.2% of participants and was similar in both vaccine groups. 269 
Other systemic events were generally mild or moderate and were reported in similar 270 
proportions in both groups. 271 
The AEs reported reflected anticipated illnesses in this age group and did not differ between 272 
groups (49.2% and 50.8% for PCV13 MDV and PCV13 SDS, respectively). The most 273 
frequently reported individual AEs were upper respiratory tract infection, viral diarrhea, and 274 
dermatitis, which were reported by similar proportions in the MDV group (23.2%, 7.6%, and 275 
6.0%) and SDS group (20.0%, 12.0%, and 8.8%). There were also 3 related AEs of pyrexia 276 
(1 event in PCV13 MDV, 2 events in PCV13 SDS) that occurred on the day of vaccination 277 
(and therefore were not captured in the e-diary). One sudden infant death occurred in the 278 
PCV13 MDV group on day 20 after dose 3; this SAE was considered unrelated to trial 279 
vaccines. 280 
Discussion 281 
This trial compared the currently licensed PCV13 SDS presentation with a novel MDV 282 
preparation containing 2-PE in Gambian infants. Results confirmed noninferiority of the new 283 
formulation for all 13 serotypes for the primary outcome measures. Specifically, proportions 284 
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of participants achieving antipneumococcal IgG antibody concentrations ≥0.35 µg/mL were 285 
noninferior for MDV compared to SDS, as were IgG GMCs. Additionally, functional 286 
antibody assessed using OPA was similar between groups. No safety concerns were raised 287 
with the new formulation. 288 
Substituting PCV13 SDS with a preparation containing multiple doses would have 289 
considerable advantages regarding logistics associated with vaccine delivery to remote areas, 290 
but equivalent safety and immunogenicity records are paramount for WHO prequalification 291 
and introduction. More than 95% of participants achieved concentrations above the WHO-292 
defined threshold for protection for all 13 serotypes, and no major differences were observed 293 
between vaccine groups based on predefined noninferiority criteria. Minor differences in 294 
GMCs noted for serotype 18C and serotype 3 between vaccine groups are not likely to be of 295 
clinical significance. Results from OPA assays confirmed that IgG concentrations were 296 
associated with functional antibody, and GMTs were similar between groups for the majority 297 
of serotypes. 298 
These results are likely generalizable, as the current trial setting is representative of other 299 
areas where MDV would be used.  300 
Solicited local and systemic reactions and AEs were generally few and mild, with no 301 
differences between vaccine arms. No new safety issues were detected, suggesting that safety 302 
profiles of MDV and SDS are at least similar. Reactogenicity was low in both groups when 303 
compared to previous studies conducted elsewhere using PCV [27]. One potential 304 
explanation for low reactogenicity is the initial day of assessment being approximately 24 305 
hours after vaccination, meaning reactions limited to the day of vaccination and resolving 306 
before day 2 could have been missed. However, this would only include reactions lasting <1 307 
day, which are likely to be mild. Related adverse events on vaccination days were also low 308 
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and similar between groups. Other vaccine trials in this setting using similar reporting 309 
methods and times have also reported low vaccine reactogenicity [28]. The recording of 310 
reactogenicity data in the e-diary from day 2 following vaccination may partially explain the 311 
disparity between proportions of participants reporting antipyretic use (13.8%–23.2%) and 312 
those with documented pyrexia (≤3.6%), as pyrexia may have developed after field workers 313 
departed on day 1 but before their return visit on day 2. Moreover, antipyretics may have 314 
been used for pyrexia perceived by parents rather than actual pyrexia.  315 
The AEs noted were similar between trial groups and were generally consistent with 316 
conditions common in this age group. One SAE occurred in the MDV group compared with 317 
none in the SDS group, but this fatal SAE occurring 20 days after dose 3 was considered 318 
unrelated to vaccination following review by the local safety monitor and DMC. Considering 319 
infant mortality in The Gambia [29], unexplained deaths in this age group are unsurprising; 320 
overall mortality in the trial was very low.  321 
In conclusion, the immune response induced by PCV13 formulated with 2-PE in multidose 322 
vials was noninferior to the immune response induced by PCV13 without 2-PE in single-dose 323 
syringes when given at approximately 2, 3, and 4 months of age with routine pediatric 324 
vaccinations in healthy infants. Therefore, PCV13 with 2-PE likely induces an immune 325 
response adequate to protect against pneumococcal disease, similar to that induced by PCV13 326 
without 2-PE. The comparable immunogenicity and safety profiles of PCV13 MDV and 327 
PCV13 SDS support use of PCV13 MDV in places where the SDS may pose unique 328 
challenges. Availability of PCV13 MDV would help ensure vaccine sustainability for infants 329 
in resource-limited settings. 330 
  331 
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Tables 481 
Table 1. Demographic Characteristics of the Population Evaluable for Immunogenicity 482 
 Vaccine Group (as Randomized)  
Characteristics 
PCV13 MDV 
Na=245 
PCV13 SDS 
Na=244 
Total 
Na=489 
Sex, n (%) 
Female 127 (51.8) 128 (52.5) 255 (52.1) 
Male 118 (48.2) 116 (47.5) 234 (47.9) 
Race, n (%) 
Black 245 (100.0) 244 (100.0) 489 (100.0) 
Ethnic Group, n (%) 
Mandinka 112 (45.7) 110 (45.1) 222 (45.4) 
Jola 42 (17.1) 47 (19.3) 89 (18.2) 
Fula 35 (14.3) 27 (11.1) 62 (12.7) 
Wolof 30 (12.2) 25 (10.2) 55 (11.2) 
Sarahule 8 (3.3) 11 (4.5) 19 (3.9) 
Other 18 (7.3) 24 (9.8) 42 (8.6) 
Age at enrollment, days 
Mean (SD) 57.2 (8.6) 56.8 (8.7) 57.0 (8.7) 
Median 58.0 56.0 57.0 
Min, Max 43.0, 71.0 43.0, 71.0 43.0, 71.0 
Weight, kg 
Mean (SD) 5.0 (0.7) 4.9 (0.7) 4.9 (0.7) 
Median 4.9 4.8 4.8 
Min, max 3.5, 7.8 3.5, 6.7 3.5, 7.8 
PCV13 MDV=13-valent pneumococcal conjugate vaccine formulated with 2-PE in multidose 483 
vials; PCV13 SDS= 13-valent pneumococcal conjugate vaccine formulated without 2-PE in 484 
single-dose syringes. 485 
aNumber of participants in the vaccine group, or total sample. These values are used as 486 
denominators for percentages. 487 
 488 
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Table 2. Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 µg/mL 1 Month After Dose 3 (Evaluable 489 
Immunogenicity Population) 490 
 
Vaccine Group (as Randomized) 
 
 
PCV13 MDV PCV13 SDS 
 Serotype Na nb % (95% CIc) Na nb % (95% CIc) Differenced (97.5% CIe) 
1 245 243 99.2 (97.1, 99.9) 244 244 100.0 (98.5, 100.0) −0.8 (–3.4, 1.2) 
3 245 242 98.8 (96.5, 99.7) 243 242 99.6 (97.7, 100.0) −0.8 (–3.7, 1.6) 
4 245 244 99.6 (97.7, 100.0) 244 243 99.6 (97.7, 100.0) 0.0 (–2.3, 2.4) 
5 245 235 95.9 (92.6, 98.0) 244 237 97.1 (94.2, 98.8) −1.2 (–5.4, 2.8) 
6A 243 234 96.3 (93.1, 98.3) 244 238 97.5 (94.7, 99.1) −1.2 (–5.3, 2.6) 
6B 245 233 95.1 (91.6, 97.4) 244 232 95.1 (91.6, 97.4) 0.0 (–4.7, 4.7) 
7F 245 244 99.6 (97.7, 100.0) 244 244 100.0 (98.5, 100.0) −0.4 (–2.7, 1.6) 
9V 245 240 98.0 (95.3, 99.3) 244 240 98.4 (95.9, 99.6) −0.4 (–3.8, 2.8) 
14 245 239 97.6 (94.7, 99.1) 244 240 98.4 (95.9, 99.6) −0.8 (–4.3, 2.5) 
18C 245 243 99.2 (97.1, 99.9) 244 239 98.0 (95.3, 99.3) 1.2 (–1.6, 4.5) 
19A 245 244 99.6 (97.7, 100.0) 244 241 98.8 (96.4, 99.7) 0.8 (–1.6, 3.6) 
19F 245 237 96.7 (93.7, 98.6) 244 237 97.1 (94.2, 98.8) −0.4 (–4.4, 3.5) 
23F 245 235 95.9 (92.6, 98.0) 244 234 95.9 (92.6, 98.0) 0.0 (–4.3, 4.4) 
IgG=immunoglobulin G; PCV13 MDV=13-valent pneumococcal conjugate vaccine formulated with 2-PE in multidose vials; 491 
PCV13 SDS= 13-valent pneumococcal conjugate vaccine formulated without 2-PE in single-dose syringes. 492 
aNumber of participants with a valid and determinate IgG concentration to the given serotype. 493 
bNumber of participants with an antibody concentration ≥0.35 µg/mL for the given serotype. 494 
cExact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. 495 
dDifference in proportions, PCV13 MDV−PCV13 SDS, expressed as a percentage. 496 
eExact 2-sided CI (based on Chan and Zhang [30]) for the difference in proportions, PCV13 MDV−PCV13 SDS, expressed as a 497 
percentage. 498 
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Table 3. Comparison of Pneumococcal IgG GMCs (µg/mL) 1 Month After Dose 3 (Evaluable Immunogenicity Population) 499 
 
Vaccine Group (as Randomized)  
 
PCV13 MDV PCV13 SDS  
Serotype na GMCb (95% CIc) na GMCb (95% CIc) Ratiod (97.5% CIe) 
1 245 4.59 (4.11, 5.12) 244 4.45 (4.01, 4.93) 1.03 (0.87, 1.22) 
3 245 1.38 (1.29, 1.49) 243 1.74 (1.62, 1.87) 0.79 (0.71, 0.90) 
4 245 5.30 (4.84, 5.81) 244 5.28 (4.76, 5.85) 1.00 (0.86, 1.18) 
5 245 2.00 (1.79, 2.22) 244 1.98 (1.79, 2.20) 1.01 (0.85, 1.19) 
6A 243 2.25 (2.02, 2.50) 244 2.19 (1.96, 2.44) 1.03 (0.86, 1.22) 
6B 245 3.42 (2.91, 4.02) 244 3.24 (2.77, 3.78) 1.06 (0.82, 1.36) 
7F 245 3.92 (3.59, 4.27) 244 4.18 (3.83, 4.55) 0.94 (0.82, 1.08) 
9V 245 2.83 (2.56, 3.13) 244 2.75 (2.49, 3.04) 1.03 (0.87, 1.21) 
14 245 4.78 (4.06, 5.63) 244 4.96 (4.27, 5.77) 0.96 (0.75, 1.24) 
18C 245 3.47 (3.17, 3.79) 244 2.72 (2.46, 3.00) 1.28 (1.09, 1.49) 
19A 245 6.49 (5.70, 7.38) 244 6.44 (5.66, 7.32) 1.01 (0.82, 1.24) 
19F 245 5.19 (4.59, 5.86) 244 5.00 (4.43, 5.63) 1.04 (0.85, 1.26) 
23F 245 2.61 (2.30, 2.97) 244 2.17 (1.92, 2.46) 1.20 (0.98, 1.48) 
GMC=geometric mean concentration; IgG=immunoglobulin G; PCV13 MDV=13-valent pneumococcal conjugate vaccine formulated 500 
with 2-PE in multidose vials; PCV13 SDS= 13-valent pneumococcal conjugate vaccine formulated without 2-PE in single-dose 501 
syringes. 502 
aNumber of participants with a valid and determinate antibody concentration for the specified serotype. 503 
bGMCs were calculated using all participants with available data for the specified blood draw. 504 
cCIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. 505 
dRatio of GMCs, PCV13 MDV to PCV13 SDS, was calculated by back transforming the mean difference between the vaccine groups 506 
on the logarithmic scale. 507 
eCIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the 508 
measures (PCV13 MDV–PCV13 SDS). 509 
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Table 4. Comparison of Pneumococcal OPA GMTs 1 Month After Dose 3 (Evaluable Immunogenicity Population)a 510 
 
Vaccine Group (as Randomized)  
 
 
PCV13 MDV PCV13 SDS  
 
Serotype nb GMTc (95% CId) nb GMTc (95% CId) Ratioe (95% CIf) 
1 159 48 (39.0, 58.0) 160 52 (43.2, 62.6) 0.9 (0.70, 1.20) 
3 160 97 (87.3, 108.8) 160 122 (110.1, 135.7) 0.8 (0.69, 0.93) 
4 159 1666 (1412.3, 1966.3) 159 1492 (1285.2, 1732.3) 1.1 (0.89, 1.39) 
5 160 79 (67.7, 92.4) 159 80 (69.1, 92.6) 1.0 (0.80, 1.22) 
6A 160 1690 (1460.5, 1955.9) 160 1968 (1698.5, 2279.3) 0.9 (0.70, 1.06) 
6B 156 1990 (1611.7, 2456.9) 155 2014 (1639.1, 2475.4) 1.0 (0.74, 1.33) 
7F 159 2891 (2565.4, 3258.5) 160 3450 (3014.7, 3947.9) 0.8 (0.70, 1.00) 
9V 158 709 (600.5, 836.2) 160 706 (597.0, 835.3) 1.0 (0.79, 1.27) 
14 157 567 (415.4, 773.5) 160 786 (607.8, 1015.3) 0.7 (0.48, 1.08) 
18C 159 2792 (2387.5, 3264.8) 160 1605 (1352.0, 1904.4) 1.7 (1.38, 2.19) 
19A 160 305 (256.2, 362.9) 160 329 (284.8, 379.8) 0.9 (0.74, 1.16) 
19F 158 430 (357.6, 517.1) 159 470 (391.4, 565.3) 0.9 (0.71, 1.18) 
23F 159 918 (729.0, 1156.4) 160 998 (810.6, 1229.6) 0.9 (0.67, 1.25) 
GMT=geometric mean titer; OPA=opsonophagocytic activity; PCV13 MDV=13-valent pneumococcal conjugate vaccine formulated 511 
with 2-PE in multidose vials; PCV13 SDS=13-valent pneumococcal conjugate vaccine formulated without 2-PE in single-dose 512 
syringes. 513 
aOPA assays were performed on the blood sample taken 1 month after dose 3 in a subset of randomly selected 514 
participants from each group. 515 
bNumber of participants with a valid and determinate antibody titer for the specified serotype. 516 
cGMTs were calculated using all participants with available data for the specified blood draw. 517 
dCIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. 518 
eRatio of GMTs, PCV13 MDV to PCV13 SDS, was calculated by back transforming the mean difference between the vaccine groups 519 
on the logarithmic scale. 520 
fCIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the 521 
measures (PCV13 MDV–PCV13 SDS). 522 
 523 
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Table 5. Subjects Reporting Local Reactions, Systemic Events, and Antipyretic Medication Use on Days 2–6 524 
Condition  
Reported 
Dose 1 Dose 2 Dose 3 
PCV13 MDV PCV13 SDS PCV13 MDV PCV13 SDS PCV13 MDV PCV13 SDS 
% (na/Nb) % (na/Nb) % (na/Nb) % (na/Nb) % (na/Nb) % (na/Nb) 
Local Reaction       
Tendernessc       
Any 16.9 (42/248) 18.8 (47/250) 13.7 (34/248) 13.0 (32/247) 15.0 (37/246) 14.5 (35/241) 
Mild 12.9 (32/248) 14.8 (37/250) 10.9 (27/248) 11.3 (28/247) 12.2 (30/246) 13.3 (32/241) 
Moderate 5.2 (13/248) 5.6 (14/250) 2.8 (7/247) 2.0 (5/247) 3.7 (9/246) 1.7 (2/241) 
Severe 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Swellingd       
Any 0.4 (1/248) 0.0 (0/250) 0.8 (2/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Mild 0.4 (1/248) 0.0 (0/250) 0.8 (2/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Moderate 0.0 (0/248) 0.0 (0/250) 0.4 (1/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Severe 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Rednessd       
Any 0.4 (1/248) 0.0 (0/250) 0.8 (2/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Mild 0.4 (1/248) 0.0 (0/250) 0.8 (2/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Moderate 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Severe 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Systemic Event       
Fevere       
≥38°C 3.6 (9/248) 2.8 (7/250) 2.8 (7/247) 2.8 (7/247) 1.2 (3/246) 3.3 (8/241) 
≥38°C but ≤39°C 3.6 (9/248) 2.8 (7/250) 2.8 (7/247) 2.8 (7/247) 1.2 (3/246) 2.9 (7/241) 
>39°C but ≤40°C 0.0 (0/248) 0.0 (0/250) 0.4 (1/247) 0.0 (0/247) 0.0 (0/246) 0.4 (1/241) 
>40°C 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 0.0 (0/247) 0.0 (0/246) 0.0 (0/241) 
Decreased appetitef       
Any 6.9 (17/248) 10.4 (26/250) 11.3 (28/247) 7.3 (18/247) 9.8 (24/246) 8.3 (20/242) 
Moderate 6.9 (17/248) 10.4 (26/250) 11.3 (28/247) 7.3 (18/247) 9.8 (24/246) 7.9 (19/242) 
Severe 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 0.0 (0/247) 0.0 (0/246) 0.4 (1/241) 
Irritabilityg       
Any 41.4 (103/249) 37.2 (93/250) 37.5 (93/248) 33.6 (83/247) 33.7 (83/246) 37.9 (92/243) 
Mild 34.5 (86/249) 30.8 (77/250) 30.2 (75/248) 27.1 (67/247) 28.9 (71/246) 30.6 (74/242) 
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Moderate 7.7 (19/248) 6.8 (17/250) 9.3 (23/247) 6.9 (17/247) 6.1 (15/246) 7.4 (18/242) 
Severe 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 1.2 (3/247) 0.4 (1/246) 2.1 (5/241) 
Increased sleeph       
Any 6.5 (16/248) 5.6 (14/250) 9.7 (24/247) 5.7 (14/247) 4.9 (12/246) 5.0 (12/241) 
Mild 4.4 (11/248) 4.0 (10/250) 8.1 (20/247) 4.9 (12/247) 4.1 (10/246) 4.6 (11/241) 
Moderate 2.4 (6/248) 1.6 (4/250) 1.6 (4/247) 0.4 (1/247) 0.8 (2/246) 0.4 (1/241) 
Severe 0.0 (0/248) 0.0 (0/250) 0.0 (0/247) 0.4 (1/247) 0.4 (1/246) 0.0 (0/241) 
Use of antipyretic 
medication 
22.2 (55/248) 23.2 (58/250) 18.5 (46/248) 17.4 (43/247) 13.8 (34/246) 14.9 (36/241) 
PCV13 MDV=13-valent pneumococcal conjugate vaccine formulated with 2-PE in multidose vials; PCV13 SDS=13-valent pneumococcal 525 
conjugate vaccine formulated without 2-PE in single-dose syringes. 526 
aNumber of subjects reporting the reaction. 527 
bNumber of subjects reporting yes for at least 1 day or no for all days. 528 
cTenderness was categorized as mild (hurts if gently touched), moderate (hurts if gently touched with crying), or severe (causes 529 
limitation of limb movement). 530 
dSwelling and redness were measured by caliper (each caliper unit representing 0.5 cm) and categorized as mild (0.5–2.0 cm), moderate 531 
(2.1–7.0 cm) or severe (>7.0 cm). 532 
eFever severity was categorized as: 38°C–39°C, 39.1°C–40°C, and >40°C. 533 
fLoss of or decreased appetite defined as moderate (decreased oral intake), or severe (refusal to feed). 534 
gIrritability defined as mild (easily consolable), moderate (requiring increased attention) or severe (inconsolable, crying that cannot be 535 
comforted). 536 
hIncreased sleep defined as drowsiness, mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfering with daily 537 
activity) or severe (disabling, not interested in usual daily activity). 538 
 539 
 540 
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Figure Legend 541 
 542 
Figure 1. CONSORT diagram. All 26 ineligible participants were excluded for failure to meet 543 
inclusion criteria or for meeting exclusion criteria: 14 (54%) weighed less than 3.5 kg, 5 (20%) 544 
suffered from an intercurrent illness and would have been too old for enrollment after the 545 
allowable window of 5 days after completing antibiotic therapy, 3 (11%) had underlying 546 
congenital anomalies, and 2 (7.5%) each were not available for the entire trial period, or had 547 
received previous pneumococcal vaccination. 548 
MDV=multidose vials; PCV13=13-valent pneumococcal conjugate vaccine; SDS=single-dose 549 
syringe. 550 
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Figure 1. 551 
 552 
 553 
 554 
526 subjects screened
Randomized
Vaccinated
Dose 1
Dose 2
Dose 3
Withdrawn during study
PCV13 MDV
250 
(100%)
5 (2·0%)
2   no longer willing to participate
1   lost to follow-up
1   no longer eligible
1   death
245 (98·0 %)
250 (100%)
249 (99·6%)
247 (98·8%)
PCV13 SDS
250 
(100%)
250 (100%)
248 (99·2%)
244 (97·6%)
244 (97·6%)
500 enrolled and randomized 1:1 (95·1%)
Completed study and included 
in immunogenicity analysis
26 (4·9%) subjects excluded (did not meet inclusion criteria)
6  (2·4%)
3 no longer willing to participate
2 lost to follow-up
1 no longer eligible
0 deaths
Vaccine allocation
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Supplementary Figure 1. Reverse Cumulative Distribution Curve of Pneumococcal 555 
OPA Antibody Titers 1 Month After PCV13 Dose 3, Evaluable Immunogenicity 556 
Population. 557 
 558 
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